{
  "pmcid": "PMC11062152",
  "pmid": "38707740",
  "title": "Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin",
  "overall_score": 0.3067683461018734,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 6,
        "items": [
          {
            "variant": "UGT1A1*6",
            "gene": "UGT1A1",
            "drug": "nanoliposomal irinotecan",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) had significantly lower nadir white blood cell counts during nal-IRI/FL treatment compared with (\u2013/\u2013) and (+/\u2013) groups (median 2,050 [1,550\u20132,513]/mm^3 vs 3,340 [2,950\u20135,120] and 3,220 [2,520\u20133,923]/mm^3; p=0.033). In multiple regression analysis, UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009). Grade 3/4 leukopenia incidence was 50.0% in (+/+) vs 7.1% and 12.5% in (\u2013/\u2013) and (+/\u2013) (p=0.085, trend).",
              "Sentence": "Genotype UGT1A1*6 or *28 (+/+) is associated with decreased nadir white blood cell counts during nanoliposomal irinotecan treatment in patients with metastatic pancreatic cancer as compared to UGT1A1*6 or *28 (\u2013/\u2013) + (+/\u2013).",
              "Alleles": "+/+",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "nadir white blood cell count during treatment with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Pancreatic Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "\u2013/\u2013 + +/\u2013",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043). Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009), high aspartate aminotransferase (AST) value before the therapy (p=0.019), and pancreatic head cancer (p=0.030). Also, the decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "The nadir counts of white blood cells in patients with UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) were 3,340 (2,950\u20135,120), 3,220 (2,520-3,923), and 2,050 (1,550-2,513)/mm^3, respectively (median with the interquartile range) (Figure 2A). \u2026 The nadir counts of white blood cells and neutrophils were significantly lower in patients with UGT1A1*6 or *28 (+/+) (p=0.033, 0.043, respectively) (Figure 2A and B).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "UGT1A1*6, UGT1A1*28",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "irinotecan",
                "drug_id": "PA450085",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "UGT1A1*28",
            "gene": "UGT1A1",
            "drug": "nanoliposomal irinotecan",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) had significantly lower nadir white blood cell counts during nal-IRI/FL treatment compared with (\u2013/\u2013) and (+/\u2013) groups (median 2,050 [1,550\u20132,513]/mm^3 vs 3,340 [2,950\u20135,120] and 3,220 [2,520\u20133,923]/mm^3; p=0.033). In multiple regression analysis, UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009). Grade 3/4 leukopenia incidence was 50.0% in (+/+) vs 7.1% and 12.5% in (\u2013/\u2013) and (+/\u2013) (p=0.085, trend).",
              "Sentence": "Genotype UGT1A1*6 or *28 (+/+) is associated with decreased nadir white blood cell counts during nanoliposomal irinotecan treatment in patients with metastatic pancreatic cancer as compared to UGT1A1*6 or *28 (\u2013/\u2013) + (+/\u2013).",
              "Alleles": "+/+",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "nadir white blood cell count during treatment with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Pancreatic Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "\u2013/\u2013 + +/\u2013",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043). Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009), high aspartate aminotransferase (AST) value before the therapy (p=0.019), and pancreatic head cancer (p=0.030). Also, the decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "The nadir counts of white blood cells in patients with UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) were 3,340 (2,950\u20135,120), 3,220 (2,520-3,923), and 2,050 (1,550-2,513)/mm^3, respectively (median with the interquartile range) (Figure 2A). \u2026 The nadir counts of white blood cells and neutrophils were significantly lower in patients with UGT1A1*6 or *28 (+/+) (p=0.033, 0.043, respectively) (Figure 2A and B).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "UGT1A1*6, UGT1A1*28",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "irinotecan",
                "drug_id": "PA450085",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "UGT1A1*6",
            "gene": "UGT1A1",
            "drug": "nanoliposomal irinotecan",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) had significantly lower neutrophil nadir counts during nal-IRI/FL treatment compared with (\u2013/\u2013) and (+/\u2013) groups (median 860 [407\u20131,616]/mm^3 vs 1,930 [1,540\u20132,782] and 1,285 [1,093\u20132,113]/mm^3; p=0.043). Multiple regression analysis showed UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017). Grade 3/4 neutropenia incidence was 50.0% in (+/+) vs 7.1% and 12.5% in (\u2013/\u2013) and (+/\u2013) (p=0.085, trend).",
              "Sentence": "Genotype UGT1A1*6 or *28 (+/+) is associated with decreased neutrophil count nadir during nanoliposomal irinotecan treatment in patients with metastatic pancreatic cancer as compared to UGT1A1*6 or *28 (\u2013/\u2013) + (+/\u2013).",
              "Alleles": "+/+",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "neutrophil count nadir during treatment with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Pancreatic Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "\u2013/\u2013 + +/\u2013",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043). Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009), high aspartate aminotransferase (AST) value before the therapy (p=0.019), and pancreatic head cancer (p=0.030). Also, the decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "The nadir counts of neutrophil in patients with UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) were 1,930 (1,540-2,782), 1,285 (1,093-2,113), and 860 (407-1,616)/mm^3, respectively (median with the interquartile range) (Figure 2B). The nadir counts of white blood cells and neutrophils were significantly lower in patients with UGT1A1*6 or *28 (+/+) (p=0.033, 0.043, respectively) (Figure 2A and B).",
                "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (\u2013/\u2013) and (+/\u2013) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "UGT1A1*6, UGT1A1*28",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "irinotecan",
                "drug_id": "PA450085",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "UGT1A1*28",
            "gene": "UGT1A1",
            "drug": "nanoliposomal irinotecan",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Patients with UGT1A1*6 or *28 (+/+) had significantly lower neutrophil nadir counts during nal-IRI/FL treatment compared with (\u2013/\u2013) and (+/\u2013) groups (median 860 [407\u20131,616]/mm^3 vs 1,930 [1,540\u20132,782] and 1,285 [1,093\u20132,113]/mm^3; p=0.043). Multiple regression analysis showed UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017). Grade 3/4 neutropenia incidence was 50.0% in (+/+) vs 7.1% and 12.5% in (\u2013/\u2013) and (+/\u2013) (p=0.085, trend).",
              "Sentence": "Genotype UGT1A1*6 or *28 (+/+) is associated with decreased neutrophil count nadir during nanoliposomal irinotecan treatment in patients with metastatic pancreatic cancer as compared to UGT1A1*6 or *28 (\u2013/\u2013) + (+/\u2013).",
              "Alleles": "+/+",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "neutrophil count nadir during treatment with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Pancreatic Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "\u2013/\u2013 + +/\u2013",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043). Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009), high aspartate aminotransferase (AST) value before the therapy (p=0.019), and pancreatic head cancer (p=0.030). Also, the decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "The nadir counts of neutrophil in patients with UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) were 1,930 (1,540-2,782), 1,285 (1,093-2,113), and 860 (407-1,616)/mm^3, respectively (median with the interquartile range) (Figure 2B). The nadir counts of white blood cells and neutrophils were significantly lower in patients with UGT1A1*6 or *28 (+/+) (p=0.033, 0.043, respectively) (Figure 2A and B).",
                "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (\u2013/\u2013) and (+/\u2013) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "UGT1A1*6, UGT1A1*28",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "irinotecan",
                "drug_id": "PA450085",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "UGT1A1*6",
            "gene": "UGT1A1",
            "drug": "nanoliposomal irinotecan",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Incidence of grade \u22651 diarrhea during nal-IRI/FL treatment did not differ significantly by UGT1A1*6 or *28 genotype: 27.3% for (\u2013/\u2013), 21.4% for (+/\u2013), and 25.0% for (+/+). Multivariate logistic regression did not identify UGT1A1 genotype as a significant predictive factor for diarrhea.",
              "Sentence": "Genotypes UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) are not associated with the incidence of diarrhea during nanoliposomal irinotecan treatment in patients with metastatic pancreatic cancer as compared to each other.",
              "Alleles": "\u2013/\u2013 + +/\u2013 + +/+",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "incidence of diarrhea during treatment with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Pancreatic Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "each other",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Diarrhea during nal-IRI/FL treatment was observed in seven (24.1%) of 29 patients, who had not been prescribed any antidiarrhea medication at the commencing time of nal-IRI. The rest of seven patients were excluded, since they received loperamide for diarrhea symptoms at the start of therapy. The incidence of grade \u22651 diarrhea in patients with *UGT1A1*6* or **28* (\u2013/\u2013), (+/\u2013), and (+/+) were 27.3%, 21.4%, and 25.0%, respectively ([Figure 1](#F1)). Multivariate analysis did not extract any risk factors, which significantly affected the development of diarrhea possibly induced by nal-IRI/FL ([Table II](#T2)).",
                "This study did not extract any risk factors that significantly influenced the development of diarrhea during nal-IRI/FL treatment (Table II)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "UGT1A1*6, UGT1A1*28",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "irinotecan",
                "drug_id": "PA450085",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "UGT1A1*28",
            "gene": "UGT1A1",
            "drug": "nanoliposomal irinotecan",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "nanoliposomal irinotecan",
              "PMID": 38707740,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Incidence of grade \u22651 diarrhea during nal-IRI/FL treatment did not differ significantly by UGT1A1*6 or *28 genotype: 27.3% for (\u2013/\u2013), 21.4% for (+/\u2013), and 25.0% for (+/+). Multivariate logistic regression did not identify UGT1A1 genotype as a significant predictive factor for diarrhea.",
              "Sentence": "Genotypes UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) are not associated with the incidence of diarrhea during nanoliposomal irinotecan treatment in patients with metastatic pancreatic cancer as compared to each other.",
              "Alleles": "\u2013/\u2013 + +/\u2013 + +/+",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "incidence of diarrhea during treatment with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Pancreatic Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "each other",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Diarrhea during nal-IRI/FL treatment was observed in seven (24.1%) of 29 patients, who had not been prescribed any antidiarrhea medication at the commencing time of nal-IRI. The rest of seven patients were excluded, since they received loperamide for diarrhea symptoms at the start of therapy. The incidence of grade \u22651 diarrhea in patients with *UGT1A1*6* or **28* (\u2013/\u2013), (+/\u2013), and (+/+) were 27.3%, 21.4%, and 25.0%, respectively ([Figure 1](#F1)). Multivariate analysis did not extract any risk factors, which significantly affected the development of diarrhea possibly induced by nal-IRI/FL ([Table II](#T2)).",
                "This study did not extract any risk factors that significantly influenced the development of diarrhea during nal-IRI/FL treatment (Table II)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "UGT1A1*6, UGT1A1*28",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "irinotecan",
                "drug_id": "PA450085",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.2953085924188296,
      "total_samples": 6,
      "ground_truth_annotations": {
        "count": 6,
        "matched_count": 2,
        "unmatched_count": 4,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8750101625919342,
            "annotation": {
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "Phenotype Category": "Toxicity",
              "Alleles": "*6 + *28",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Diarrhea",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*28",
                "prediction": "UGT1A1*28",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "fluorouracil, irinotecan, leucovorin",
                "prediction": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
                "score": 0.9550724029541016,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*6 + *28",
                "prediction": "*28",
                "score": 0.9546118974685669,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Diarrhea",
                "prediction": "Side Effect:Leukopenia, Side Effect:Neutropenia",
                "score": 0.9291527271270752,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "UGT1A1*6 or *28 (\u2013/\u2013) or (+/\u2013)",
                "score": 0.9112645983695984,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8746118724346161,
            "annotation": {
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "Phenotype Category": "Toxicity",
              "Alleles": "*6 + *28",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Diarrhea",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "UGT1A1*6",
                "prediction": "UGT1A1*6",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "UGT1A1",
                "prediction": "UGT1A1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "fluorouracil, irinotecan, leucovorin",
                "prediction": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
                "score": 0.9550724029541016,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*6 + *28",
                "prediction": "*6",
                "score": 0.9506289958953857,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Diarrhea",
                "prediction": "Side Effect:Leukopenia, Side Effect:Neutropenia",
                "score": 0.9291527271270752,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "UGT1A1*6 or *28 (\u2013/\u2013) or (+/\u2013)",
                "score": 0.9112645983695984,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452474670,
              "Variant/Haplotypes": "UGT1A1*1",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "Diarrhea during nal-IRI/FL treatment was observed in seven (24.1%) of 29 patients, who had not been prescribed any antidiarrhea medication at the commencing time of nal-IRI. The rest of seven patients were excluded, since they received loperamide for diarrhea symptoms at the start of therapy. The incidence of grade \u22651 diarrhea in patients with UGT1A1*6 or *28 (-/-), (+/-), and (+/+) were 27.3%, 21.4%, and 25.0%, respectively (Figure 1). Multivariate analysis did not extract any risk factors, which significantly affected the development of diarrhea possibly induced by nal-IRI/FL",
              "Sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
              "Alleles": "*6 + *28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Diarrhea",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38707740",
              "Variant Annotation ID_norm": "1452474670",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452474678,
              "Variant/Haplotypes": "UGT1A1*1",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (-/-) and (+/-) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)",
              "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
              "Alleles": "*6/*6 + *28/*28 + *6/*28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38707740",
              "Variant Annotation ID_norm": "1452474678",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452474678,
              "Variant/Haplotypes": "UGT1A1*6",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (-/-) and (+/-) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)",
              "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
              "Alleles": "*6/*6 + *28/*28 + *6/*28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38707740",
              "Variant Annotation ID_norm": "1452474678",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452474678,
              "Variant/Haplotypes": "UGT1A1*28",
              "Gene": "UGT1A1",
              "Drug(s)": "fluorouracil, irinotecan, leucovorin",
              "PMID": 38707740,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (-/-) and (+/-) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)",
              "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
              "Alleles": "*6/*6 + *28/*28 + *6/*28",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
              "Multiple phenotypes And/or": "or",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "38707740",
              "Variant Annotation ID_norm": "1452474678",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.7841104957792494,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 3,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.702011203064638,
            "annotation": {
              "Study Parameters ID": 1452474688,
              "Variant Annotation ID": 1452474678,
              "Study Type": null,
              "Study Cases": 31.0,
              "Study Controls": null,
              "Characteristics": "predictive factors for neutropenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.017",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452474688,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452474678,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 31.0,
                "prediction": 36,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "predictive factors for neutropenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                "prediction": "Multiple regression analysis in Japanese metastatic pancreatic cancer patients on nal-IRI/FL: effect of UGT1A1*6 or *28 (+/+) genotype on decreased neutrophil count (neutropenia)",
                "score": 0.9341904520988464,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.017",
                "prediction": "= 0.017",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7019231144119712,
            "annotation": {
              "Study Parameters ID": 1452474729,
              "Variant Annotation ID": 1452474678,
              "Study Type": null,
              "Study Cases": 31.0,
              "Study Controls": null,
              "Characteristics": "predictive factors for leukopenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.009",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452474729,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452474678,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 31.0,
                "prediction": 36,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "predictive factors for leukopenia (multiple regression) during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                "prediction": "Multiple regression analysis in Japanese metastatic pancreatic cancer patients on nal-IRI/FL: effect of UGT1A1*6 or *28 (+/+) genotype on decreased white blood cell count (leukopenia)",
                "score": 0.9326929450035095,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.009",
                "prediction": "= 0.009",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6716522889978745,
            "annotation": {
              "Study Parameters ID": 1452474677,
              "Variant Annotation ID": 1452474670,
              "Study Type": null,
              "Study Cases": 29.0,
              "Study Controls": null,
              "Characteristics": "diarrhea greater than grade 1 during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.943",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452474677,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452474670,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "retrospective",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 29.0,
                "prediction": 36,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "diarrhea greater than grade 1 during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
                "prediction": "Japanese patients with metastatic pancreatic cancer treated with nal-IRI/FL, stratified by UGT1A1*6 or *28 genotype (\u2013/\u2013, +/\u2013, +/+); association with neutrophil nadir counts",
                "score": 0.9180889129638672,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.943",
                "prediction": "= 0.043",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 3,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "retrospective",
              "Study Cases": 36,
              "Study Controls": null,
              "Characteristics": "Japanese patients with metastatic pancreatic cancer treated with nal-IRI/FL, stratified by UGT1A1*6 or *28 genotype (\u2013/\u2013, +/\u2013, +/+)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.033",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "retrospective",
              "Study Cases": 36,
              "Study Controls": null,
              "Characteristics": "Multiple regression analysis in Japanese metastatic pancreatic cancer patients on nal-IRI/FL: effect of high AST value before therapy on decreased white blood cell count (leukopenia)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.019",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": null,
              "Variant Annotation ID": null,
              "Study Type": "retrospective",
              "Study Cases": 36,
              "Study Controls": null,
              "Characteristics": "Multiple regression analysis in Japanese metastatic pancreatic cancer patients on nal-IRI/FL: effect of pancreatic head tumor location on decreased white blood cell count (leukopenia)",
              "Characteristics Type": "disease",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.030",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}